Laboratorio Reig Jofre (XMAD:RJF) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:RJF Laboratorio Reig Jofre SA XMAD:RJF
80 GF Score
Price €2.62
GF Value €2.72
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Laboratorio Reig Jofre Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Laboratorio Reig Jofre is: Moderate Risk: Sensitive, better choose undervalued stock.

Laboratorio Reig Jofre  (XMAD:RJF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Laboratorio Reig Jofre Risk Assessment Related Terms

XMAD:RJF vs ZTS, UTHR, VTRS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorio Reig Jofre Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's Risk Assessment falls into.


XMAD:RJF
80GF Score
Laboratorio Reig Jofre SA XMAD:RJF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued. The current stock price of €2.62 is trading 3.7% below its estimated GF Value™ of €2.72. GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.

Key valuation signals for XMAD:RJF:

  • Risk Assessment:
  • GF Value™: €2.72 vs. price of €2.62 (3.7% below fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorio Reig Jofre Business Description

Other Exchanges 0RB1:UKFEQ1:Germany
Address Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
80GF Score

Get the complete analysis for XMAD:RJF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.62
Price
€2.72
GF Value